KBC Group NV Buys 650 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

KBC Group NV grew its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 43.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 2,159 shares of the company’s stock after buying an additional 650 shares during the period. KBC Group NV’s holdings in Amphastar Pharmaceuticals were worth $80,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in AMPH. Victory Capital Management Inc. raised its holdings in Amphastar Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock worth $10,605,000 after purchasing an additional 21,530 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Amphastar Pharmaceuticals in the third quarter valued at $11,070,000. Wellington Management Group LLP acquired a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth about $957,000. XTX Topco Ltd acquired a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at about $674,000. Finally, Geode Capital Management LLC grew its stake in Amphastar Pharmaceuticals by 1.5% during the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock worth $44,674,000 after purchasing an additional 14,015 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AMPH. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $66.00 to $36.00 in a research report on Tuesday, February 4th. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price objective on the stock. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $50.33.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $32.37 on Monday. Amphastar Pharmaceuticals, Inc. has a 1-year low of $32.16 and a 1-year high of $56.45. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a market cap of $1.56 billion, a price-to-earnings ratio of 10.79, a PEG ratio of 2.07 and a beta of 0.81. The company’s fifty day moving average price is $38.14 and its two-hundred day moving average price is $43.71.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $43.77, for a total value of $437,700.00. Following the sale, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. The trade was a 24.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Rong Zhou sold 7,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total transaction of $310,940.00. Following the completion of the sale, the executive vice president now directly owns 118,469 shares in the company, valued at approximately $5,262,392.98. This represents a 5.58 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,893 shares of company stock worth $1,329,570 in the last quarter. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.